Authors
Suetonia C Palmer, Sankar D Navaneethan, Jonathan C Craig, David W Johnson, Marcello Tonelli, Amit X Garg, Fabio Pellegrini, Pietro Ravani, Meg Jardine, Vlado Perkovic, Giusi Graziano, Richard McGee, Antonio Nicolucci, Gianni Tognoni, Giovanni FM Strippoli
Publication date
2010/7/6
Source
Annals of internal medicine
Volume
153
Issue
1
Pages
23-33
Publisher
American College of Physicians
Description
Background
Previous meta-analyses suggest that treatment with erythropoiesis-stimulating agents (ESAs) in chronic kidney disease (CKD) increases the risk for death. Additional randomized trials have been recently completed.
Purpose
To summarize the effects of ESA treatment on clinical outcomes in patients with anemia and CKD.
Data Sources
MEDLINE (January 1966 to November 2009), EMBASE (January 1980 to November 2009), and the Cochrane database (to March 2010) were searched without language restriction.
Study Selection
Two authors independently screened reports to identify randomized trials evaluating ESA treatment in people with CKD. Hemoglobin target trials or trials of ESA versus no treatment or placebo were included.
Data Extraction
Two …
Total citations
Scholar articles
SC Palmer, SD Navaneethan, JC Craig, DW Johnson… - Annals of internal medicine, 2010